ArriVent's firmonertinib shows 68% response rate at 240 mg in EGFR PACC-mutant lung cancer trial
AVBP•ArriVent Biopharma reported a 68% confirmed response rate and median progression-free survival of 16.0 months at the 240 mg dose in a Phase 1b trial for previously untreated advanced EGFR PACC-mutant non-small cell lung cancer. The global Phase 3 ALPACCA trial is enrolling patients.
1. Phase 1b results
ArriVent Biopharma announced publication in Cancer Cell of Phase 1b firmonertinib results in previously untreated advanced EGFR PACC-mutant non-small cell lung cancer. The 240 mg dose achieved a 68% confirmed response rate and median progression-free survival of 16.0 months; at 160 mg, those results were 43% and 11.1 months.
2. Brain metastases and Phase 3
Among 17 patients with baseline brain metastases, the confirmed intracranial response rate was 47%, including 41% complete responses. The global Phase 3 ALPACCA trial continues enrolling patients and compares firmonertinib with osimertinib or afatinib as first-line treatment.
